AIO Part I: Interpretable ADMET Prediction for Cyclic Peptides and Macrocycles

Macrocycles and cyclic peptides are increasingly important in beyond-rule-of-five (bRo5) drug discovery, yet their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties remain difficult to predict owing to sparse data, complex topology, and environment-dependent conformations. Here, we present AIO (All-in-One), an interpretable multimodal ADMET framework combining topology-preserving molecular segmentation with solvent-aware contrastive pretraining. Across repeated cross-validation, AIO performed strongly across permeability, solubility, unbound fraction, clearance, half-life, bioavailability, and toxicity endpoints, achieving Pearson R = 0.87 for PAMPA permeability and AUROC = 0.91 for bioavailability. Case studies of recently approved macrocyclic and cyclic-peptide drugs showed agreement between predictions and reported pharmacokinetic profiles, while segment-level attribution highlighted molecular regions associated with predicted ADMET bottlenecks. Despite pretraining exclusively on macrocycles, AIO also transferred competitively to the small-molecule PharmaBench dataset. These results establish a promising foundation for interpretable ADMET prediction across diverse molecular modalities in drug discovery.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.18.767182
Primary Topic
Computational Drug Discovery Methods
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

AIO Part I: Interpretable ADMET Prediction for Cyclic Peptides and Macrocycles

Yue Hong Qian, Sicheng Wen, Shu Wang
bioRxiv (Cold Spring Harbor Laboratory)
Computational Drug Discovery Methods
preprint

AIO Part I: Interpretable ADMET Prediction for Cyclic Peptides and Macrocycles

Yue Hong Qian, Sicheng Wen, Shu Wang
preprint en

Abstract

Macrocycles and cyclic peptides are increasingly important in beyond-rule-of-five (bRo5) drug discovery, yet their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties remain difficult to predict owing to sparse data, complex topology, and environment-dependent conformations. Here, we present AIO (All-in-One), an interpretable multimodal ADMET framework combining topology-preserving molecular segmentation with solvent-aware contrastive pretraining. Across repeated cross-validation, AIO performed strongly across permeability, solubility, unbound fraction, clearance, half-life, bioavailability, and toxicity endpoints, achieving Pearson R = 0.87 for PAMPA permeability and AUROC = 0.91 for bioavailability. Case studies of recently approved macrocyclic and cyclic-peptide drugs showed agreement between predictions and reported pharmacokinetic profiles, while segment-level attribution highlighted molecular regions associated with predicted ADMET bottlenecks. Despite pretraining exclusively on macrocycles, AIO also transferred competitively to the small-molecule PharmaBench dataset. These results establish a promising foundation for interpretable ADMET prediction across diverse molecular modalities in drug discovery.

bioRxiv (Cold Spring Harbor Laboratory)
Viva Biotech (China) (CN)
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon